Study disease biology
Represent selected cells, matrix and spatial interactions to test a biological hypothesis.
Drug-discovery guide
Build the model around a decision.
3D bioprinting can create structured human-cell models for research and preclinical workflows. Adoption depends on more than biological promise. Teams need a defined use, repeatable performance and a practical route into the laboratory.
Potential role
Human relevance must serve a defined purpose.
A model might be used to investigate mechanism, compare candidate response, develop an assay or explore a safety question. The design and evidence requirement change with that purpose.
Compare a response
Define the treatment, control, readout and result that could change a programme decision.
Prepare for transfer
Design repeatability, throughput, handling and downstream analysis into the model-development plan.
Development framework
Six questions make the brief more useful.
- 01
What decision?
State the programme action the model output could inform.
- 02
Which biology?
Identify the human cells, structures and interactions relevant to that decision.
- 03
Which comparator?
Define the current model, reference method, controls and known response.
- 04
Which readout?
Specify the assay, instrumentation, sampling points and analysis route.
- 05
What performance?
Set acceptance criteria for biological response, repeatability and robustness.
- 06
What operating fit?
Include throughput, automation, operator, transfer, cost and support requirements.
The translation gap
Promising biology is not the same as an adoptable model.
The 2026 ABPI and NC3Rs landscape review found that many academic in vitro models need further work on robustness, validation, standardisation and scalability before routine industry use. Website claims should therefore show the development pathway and current evidence boundary.
- Characterised cells and materials
- Documented methods and controls
- Repeatability within and between runs
- Performance against the intended context
- Transfer, scale and workflow compatibility
Regulatory context
Momentum is increasing, but qualification remains use-specific.
UK and US policy supports development and adoption of human-relevant new approach methodologies. That does not make every 3D model regulator accepted. Evidence, validation and early regulator engagement may be required depending on the intended use.
ABPI and NC3Rs translational readiness reviewUK alternative-methods strategy
FDA roadmap announcement
OECD Good In Vitro Method Practices
Frequently asked questions
Separate potential from proof.
How can 3D bioprinting support drug discovery?
It can help create structured in vitro models for studying disease biology, therapeutic response and selected safety questions. Value depends on whether the model is relevant, reproducible and connected to a defined programme decision.
What does context of use mean?
Context of use describes where and why a model will be used, what it measures and how its output will inform a decision. A narrowly defined context makes the required evidence clearer.
Does a more complex model automatically provide better data?
No. Added complexity is useful only when it represents biology that matters to the question and remains measurable, reproducible and practical within the workflow.
What evidence is needed before wider adoption?
Requirements commonly include biological relevance, clear controls, within-run and between-run repeatability, robustness, scalability, transferability and compatibility with downstream analysis. The exact threshold depends on the intended use.
Start a useful conversation
Turn a programme question into a feasibility brief.
Share the context of use, current model, readout, throughput and evidence threshold. JetBio can assess the fit confidentially.